Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA)

This study has been terminated.
(Preliminary data from this study does not support expected inhibition of GH and IGF-1)
Information provided by (Responsible Party):
Ipsen Identifier:
First received: October 13, 2009
Last updated: October 10, 2013
Last verified: October 2013

The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.

Condition Intervention Phase
Drug: BIM 23A760
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Proportion of patients with mean growth hormone (GH)≤2.5 ng/mL and normalised insulin-like growth factor-1 (IGF-1) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients with mean GH≤2.5 ng/mL and normalised IGF-1 [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Ring finger measurement [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Clinical laboratory tests [ Time Frame: Every visit ] [ Designated as safety issue: Yes ]
  • Adverse events [ Time Frame: At every visit ] [ Designated as safety issue: Yes ]

Enrollment: 108
Study Start Date: October 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIM 23A760 1 mg Drug: BIM 23A760
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Experimental: BIM 23A760 2 mg Drug: BIM 23A760
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Experimental: BIM 23A760 4 mg Drug: BIM 23A760
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Experimental: BIM 23A760 6 mg Drug: BIM 23A760
Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • IGF-1 ≥1.3 x upper limit normal (ULN)
  • Nadir serum GH concentration ≥0.4 ng/mL in an oral glucose tolerance test (OGTT)
  • Patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulin-like growth factor-1 (IGF-1) levels.

Exclusion Criteria:

  • The patient has received long acting somatostatin analogues within 6 months of study entry
  • The patient has undergone radiotherapy at any time prior to study entry
  • The time between pituitary surgery (if any) and study entry is less than 6 weeks
  • The patient suffers from macroadenoma with visual field defects due to chiasmatic compression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00994214

  Hide Study Locations
United States, California
Pituitary Center
Los Angeles, California, United States, 90048
United States, Massachusetts
Massachusetts General Hospital / Neuroendocrine Unit
Boston, Massachusetts, United States, 02114
United States, Oregon
Oregon University, Dept. of Endocrinology and Neurosurgery
Portland, Oregon, United States, 97239
UZ Leuven
Leuven, Belgium, 3000
Centre Hospitalier Universitaire de Liège
Liège, Belgium, B-4000
Hospital Universitário Clementino Fraga Filho
Rio de Janeiro, Brazil, 21941-913
Hospital das Clínicas de São Paulo
Sao Paulo, Brazil, 05403-0000
Czech Republic
University Hospital Olomouc, Clinic of Internal Medicine
Olomouc, Czech Republic, 775 20
General University Hospital, Clinic of Internal Medicine,
Praha, Czech Republic, 128 08
Hôpital Bicêtre
Le Kremlin Bicêtre, France, 94275 Cedex
Hôpital de la Timone
Marseille, France, 13385 Cedex 05
P. Stradins Clinical University Hospital
Riga, Latvia, LV 1002
Kaunas Medical University Hospital
Kaunas, Lithuania, LT-50009
Vilnius University Hospital "Santariskiu Klinikos"
Vilnius, Lithuania, LT-08661
UIM Endocrinología Experimental, Hospital de Especialidades
Mexico City, Mexico, DF
Insituto Nacional de Neurologia y Neurocirugia
México City, Mexico, 14269 México
Department of Endocrinology, Erasmus MC
Rotterdam, Netherlands, 3000 CA
Voivodeship Specialistic Hospital No 3
Rybnik, Poland, 44-200
"C.I. Parhon" National Institute of Endocrinology
Bucharest, Romania, 011863
Karolinska University Hospital
Stockholm, Sweden, 171 76
Academy of Medical Science of Ukraine, Department of Clinical Endocrinology
Kharkiv, Ukraine, 61002
Administration of Medical Services and Rehabilitation of "ARTEM"
Kyiv, Ukraine, 04050
National Medical University n.a. M.I.Pirogov
Vinnitsa, Ukraine, 21010
Sponsors and Collaborators
Study Director: Catherine Lesage, MD Ipsen
  More Information

No publications provided

Responsible Party: Ipsen Identifier: NCT00994214     History of Changes
Other Study ID Numbers: 2-55-52060-003
Study First Received: October 13, 2009
Last Updated: October 10, 2013
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Czech Republic: State Institute for Drug Control
Lithuania: State Medicine Control Agency - Ministry of Health
Latvia: State Agency of Medicines
Germany: Federal Institute for Drugs and Medical Devices
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
Romania: National Medicines Agency
Ukraine: State Pharmacological Center - Ministry of Health
Italy: The Italian Medicines Agency
Mexico: Ethics Committee
Brazil: Ethics Committee
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Canada: Health Products and Food Branch (HPFB)

Additional relevant MeSH terms:
Bone Diseases
Bone Diseases, Endocrine
Brain Diseases
Central Nervous System Diseases
Endocrine System Diseases
Hypothalamic Diseases
Musculoskeletal Diseases
Nervous System Diseases
Pituitary Diseases
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Dopamine Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses processed this record on November 20, 2014